공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

글루카곤 유사 펩타이드 2(GLP2R) : 파이프라인 리뷰

Glucagon Like Peptide 2 Receptor (GLP2R) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 386360
페이지 정보 영문 75 Pages
가격
US $ 3,500 ₩ 4,191,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,382,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,573,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


글루카곤 유사 펩타이드 2(GLP2R) : 파이프라인 리뷰 Glucagon Like Peptide 2 Receptor (GLP2R) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 75 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

글루카곤 유사 펩타이드 2(GLP2R)를 표적으로 하는 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보 등을 최신 뉴스 및 발표와 함께 전해드립니다.

서론

  • 조사 범위

글루카곤 유사 펩타이드 2(GLP2R) 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 범위별
  • 개발중인 제품 : 적응증별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품(Monotherapy Products)별/병용요법 제품(Combination Products)별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Naia Limited
  • Shire Plc
  • Tasly Pharmaceutical Group Co., Ltd.
  • Zealand Pharma A/S

약제 프로파일

휴지상태인 프로젝트

주요 뉴스와 프레스 릴리스

부록

LSH 16.11.21

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by 9 Meters Biopharma Inc, 2021
  • Pipeline by Applied Molecular Transport Inc, 2021
  • Pipeline by Bainan Biotech ApS, 2021
  • Pipeline by Entera Bio Ltd, 2021
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
  • Pipeline by Huons Global Co Ltd, 2021
  • Pipeline by OPKO Health Inc, 2021
  • Pipeline by PhaseBio Pharmaceuticals Inc, 2021
  • Pipeline by Sosei Group Corp, 2021
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
  • Pipeline by VectivBio Holding AG, 2021
  • Pipeline by Zealand Pharma AS, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 7, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders and Other Diseases which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Osteoporosis, Unspecified Gastrointestinal Disorders and Unspecified Metabolic Disorders.

The latest report Glucagon Like Peptide 2 Receptor - Drugs In Development, 2021, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
  • 9 Meters Biopharma Inc
  • Applied Molecular Transport Inc
  • Bainan Biotech ApS
  • Entera Bio Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Huons Global Co Ltd
  • OPKO Health Inc
  • PhaseBio Pharmaceuticals Inc
  • Sosei Group Corp
  • Tasly Pharmaceutical Group Co Ltd
  • VectivBio Holding AG
  • Zealand Pharma AS
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
  • apraglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dapiglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glepaglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GXG-8 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HL-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-15912 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOD-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NB-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize GLP2R for Unspecified Gastrointestinal Diseases and Unspecified Metabolic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 19, 2021: Zealand Pharma announces first patient dosed in EASE-SBS 4 phase 3b trial assessing glepaglutide in patients with short bowel syndrome
  • Jun 29, 2021: Zealand Pharma to present data on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)
  • Jun 24, 2021: VectivBio receives FDA Orphan Drug Designation for apraglutide for acute graft-versus-host disease
  • Jun 23, 2021: Takeda Pharmaceutical : Obtaining manufacturing and marketing approval for "Revestive", the first treatment for short bowel syndrome in Japan
  • Jun 15, 2021: VectivBio announces first patient dosed in metabolic balance study of apraglutide in colon-in-continuity patients with short bowel syndrome with intestinal failure
  • Apr 07, 2021: Hanmi's short bowel syndrome drug gets FDA fast-track status
  • Feb 03, 2021: VectivBio announces first patient dosed in pivotal phase 3 trial of Apraglutide for the treatment of short bowel syndrome
  • Feb 03, 2021: VectivBio announces first patient dosed in pivotal phase 3 trial of Apraglutide for the treatment of short bowel syndrome
  • Dec 09, 2020: 9 Meters Biopharma receives orphan drug designation for NM-003, a proprietary long-acting GLP-2, for prevention of acute graft versus host disease (aGvHD)
  • Jul 01, 2020: Hanmi Pharm's short-bowel syndrome drug wins FDA's rare pediatric disease status
  • Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland
  • Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
  • May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
  • May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
  • May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q